BRCA+   

Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...

Do you perceive a difference between somatic vs germline BRCA mutations? 

Would you ever consider using these in sequence?

OlympiA trial did not include her2+ breast cancer. 

The OncotypeDx score was 51 in this scenario. 

Young patient, germline BRCA carrier with cT1cN0 to ypT2N0 disease after docetaxel/ cyclophosphamide x 4.

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...

Would you continue pembrolizumab? Would you introduce olaparib? If using both, how would you sequence? 

This situation can feel uncomfortable.  Would this feel safer if patient is s/p mastectomy and had TNBC?

Do any studies support this rationale? Does the presence of a somatic vs germline BRCA mutation impact your decision?

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 

How do the 5 year results of SOLO-1 at ESMO 2020 impact your recommendations?

Is MDS/AML risk increased with longer duration of therapy?